Company Overview
Company Type: Private Company
Website: www.deepgenomics.com
Number of Employees: -
Year Founded: 2014
Total Amount Raised (CAD mm)†: 239.63
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Deep Genomics Inc., an artificial intelligence (AI) therapeutics company, develops genetic medicines by creating AI systems for drug discovery and development, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company develops and markets therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company develops oligonucleotide therapies that target the genetic determinants of disease at the level of RNA or DNA. The company was incorporated in 2014 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
O'Callaghan, Brian 
CEO & Director
Frey, Brendan 
Founder, Chief Innovation Officer & Director
Johnston, David B.
Chief Financial Officer
Strapps, Walter R.
Chief Scientific Officer
Pollak, Hyla 
Vice President of People Operations
Deshwar, Amit 
Senior VP & Head of Platform
Rostamianfar, Asha 
Head of Software & Data Engineering
Simpson, Troy 
VP & Head of Research Operations

Key Board Members
Name
Title
Baird, William D.
Chairman & Lead Independent Director
O'Callaghan, Brian 
CEO & Director
Frey, Brendan 
Founder, Chief Innovation Officer & Director
Bermingham, Nessan
Director
Cahill, Matt 
Director
Cook, Jennifer E.
Member of Strategic Advisory Board
D’Augelli, Adam 
Director
Damha, Masad J.
Member of Scientific Advisory Board
Dowdy, Steven F.
Member of Scientific Advisory Board
Edbrooke, Mark 
Member of Scientific Advisory Board
Fok, Jacqueline 
Director
Hutt, Peter Barton
Member of Strategic Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
MaRS Centre 661 University Avenue Suite 480 | Toronto, ON | M5G 1M1 | Canada
Phone: 647 598 8879   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Alexandria Venture Investments, LLC
Jul-28-2021
Minority
-
Series C
Canada Pension Plan Investment Board
Jul-28-2021
Minority
-
Series C
Fidelity Management & Research Company LLC
Jul-28-2021
Minority
-
Series C
SoftBank Investment Advisers (UK) Limited
Jul-28-2021
Minority
-
Series C
Amplitude Ventures
Jan-07-2020
Unknown
-
Series B


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-28-2021
Jul-28-2021
Private Placement
Target
Deep Genomics Inc.
True Venture Management, LLC,Khosla Ventures, LLC,Amplitude Ventures,Magnetic Ventures,SoftBank Investment Advisers (UK) Limited,Fidelity Management & Research Company LLC,Alexandria Venture Investments, LLC,Canada Pension Plan Investment Board Buyer Funds:SoftBank Vision Fund II-2 L.P.

143.19
Jan-07-2020
Jan-07-2020
Private Placement
Target
Deep Genomics Inc.
True Venture Management, LLC,Khosla Ventures, LLC,Future Ventures,Amplitude Ventures,Magnetic Ventures

30.74
Sep-25-2017
Sep-25-2017
Private Placement
Target
Deep Genomics Inc.
True Venture Management, LLC,Khosla Ventures, LLC

13.00
Nov-18-2015
Nov-18-2015
Private Placement
Target
Deep Genomics Inc.
True Venture Management, LLC,Bloomberg Beta L.P. Buyer Funds:Bloomberg Beta

3.70
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Product-Related Announcements
Deep Genomics Introduces the Most Advanced AI Foundation Model for RNA Disease Mechanisms and Candidate Therapeutics
Sep-15-2023
Executive Changes - CEO
Deep Genomics Announces the Appointment of Brian O’Callaghan as CEO
Apr-26-2023
Company Conference Presentations
Deep Genomics Inc. Presents at 2023 Bloom Burton & Co. Healthcare Investor Conference, Apr-26-2023 10:30 AM
Jan-06-2023
Executive/Board Changes - Other
Deep Genomics Announces Additions to Its Board of Directors and Scientific Advisory Board
Sep-19-2022
Company Conference Presentations
Deep Genomics Inc. Presents at New Product Planning Summit, Sep-19-2022


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Univdatos Market Insights
Univdatos Market Insights Research Team
Jun 15, 2021 10:35 AM
Deep Genomics Inc.
Company Profile: BioMarin Pharmaceuticals-2021
Reporting Results*
14
Infinata, Inc.
Infinata Research
Mar 19, 2020 06:31 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 16, 2019 05:40 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:34 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 17, 2019 09:06 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 18, 2019 07:09 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Dec 10, 2018 06:14 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Sep 17, 2018 07:15 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
7
Infinata, Inc.
Infinata Research
Jun 25, 2018 06:46 AM
Deep Genomics Inc.
Deep Genomics Inc. - Company Report
Reports
7


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Baird, William D.
Chairman & Lead Independent Director
(609) 662-5084
-

O'Callaghan, Brian 
CEO & Director
647 598 8879
-

Frey, Brendan 
Founder, Chief Innovation Officer & Director
647 598 8879
-

Bermingham, Nessan
Director
617 849 0203
-
-
Cahill, Matt 
Director
647 598 8879
-

Cook, Jennifer E.
Member of Strategic Advisory Board
647 598 8879
-

D’Augelli, Adam 
Director
647 598 8879
-

Damha, Masad J.
Member of Scientific Advisory Board
647 598 8879
-

Dowdy, Steven F.
Member of Scientific Advisory Board
647 598 8879
-

Edbrooke, Mark 
Member of Scientific Advisory Board
647 598 8879
-

Fok, Jacqueline 
Director
647 598 8879
-

Hutt, Peter Barton
Member of Strategic Advisory Board
647 598 8879
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
O'Callaghan, Brian 
CEO & Director
647 598 8879
-

Frey, Brendan 
Founder, Chief Innovation Officer & Director
647 598 8879
-

Johnston, David B.
Chief Financial Officer
647 598 8879
-

Strapps, Walter R.
Chief Scientific Officer
647 598 8879
-

Pollak, Hyla 
Vice President of People Operations
647 598 8879
-

Deshwar, Amit 
Senior VP & Head of Platform
647 598 8879
-

Rostamianfar, Asha 
Head of Software & Data Engineering
647 598 8879
-

Simpson, Troy 
VP & Head of Research Operations
647 598 8879
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
